The world needs Garp, according to Abbvie

In the search for immuno-oncology mechanisms that can improve on PD-(L)1 blockade Abbvie is putting a major effort behind Garp. Yesterday the group pledged to take its Argenx-derived anti-Garp MAb ABBV-151 into further trials, citing this as one reason why its R&D bill would increase from $6.5bn last year to $6.8bn in 2023.